Skip to search formSkip to main contentSkip to account menu

IPI 493

Known as: IPI-493, IPI493 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Oral Hsp90 Inhibitor IPI-493tanespimycin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Abstract 2827: Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Heat shock protein 90 (Hsp90) plays a role in… 
2011
2011
Cancer Therapy : Preclinical The Novel HSP 90 Inhibitor , IPI-493 , Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations
Purpose: KIT activity is crucial for gastrointestinal stromal tumors (GIST). Imatinib (IMA) and sunitinib (SUN) are very… 
2011
2011
Abstract 1601: Hsp90 inhibition results in a significant delay in tumor progression in a model of emerging EGFR TKI resistance in non-small cell lung cancer
Heat shock protein 90 (Hsp90) plays a role in regulating the stability of key cancer-causing proteins through its role as a… 
2008
2008
153 POSTER IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)